Home > Oncology > ELCC 2022 > Advanced Non-Small Cell Lung Cancer > No impact of grade ≥2 pneumonitis on patient-reported outcomes in PACIFIC

No impact of grade ≥2 pneumonitis on patient-reported outcomes in PACIFIC

Presented By
Prof. Rina Hui, University of Sydney, Australia
Conference
ELCC 2022
Trial
Phase 3, PACIFIC
Doi
https://doi.org/10.55788/262caa8a
Patient-reported outcomes of the phase 3 PACIFIC trial indicated that durvalumab did not have a detrimental impact on patient quality of life (QoL) compared with placebo, irrespective of whether patients experienced grade ≥2 pneumonitis. The phase 3 PACIFIC trial (NCT02125461) demonstrated that maintenance therapy with the immune checkpoint inhibitor durvalumab after completion of concurrent chemoradiotherapy (CRT) significantly improves progression-free and 5-year overall survival in patients with unresectable non-small cell lung cancer (NSCLC) [1,2]. Any-grade pneumonitis (including radiation-pneumonitis) was among the most common adverse events in PACIFIC, occurring in 33.9% and 24.8% of participants on durvalumab and placebo, respectively [2]. Pneumonitis predominantly occurred with low-grade severity, and a prior exploratory analysis from PACIFIC suggested...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on